Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome-negative CML”

135 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 135 results

Not applicableNo Longer AvailableNCT01549548
What this trial is testing

Compassionate Use Ponatinib

Who this might be right for
Philadelphia Chromosome Positive (Ph+) LeukemiasChronic Myeloid Leukemia
OHSU Knight Cancer Institute
Early research (Phase 1)Study completedNCT00807677
What this trial is testing

Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more
Millennium Pharmaceuticals, Inc. 31
Not applicableNo Longer AvailableNCT04518644
What this trial is testing

Nilotinib, for Patients With CML-CP or CML-AP

Who this might be right for
Chronic Myelogenous Leukemia (CML)
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT01511289
What this trial is testing

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more
Il-Yang Pharm. Co., Ltd. 242
Large-scale testing (Phase 3)Study completedNCT01743989
What this trial is testing

Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

Who this might be right for
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis Pharmaceuticals 620
Large-scale testing (Phase 3)Active Not RecruitingNCT05456191
What this trial is testing

Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals 568
Post-approval studies (Phase 4)Study completedNCT06427811
What this trial is testing

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals 85
Early research (Phase 1)Study completedNCT01220648
What this trial is testing

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 4
Early research (Phase 1)Ended earlyNCT00860535
What this trial is testing

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Who this might be right for
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Merck Sharp & Dohme LLC 9
Early research (Phase 1)Study completedNCT02081378
What this trial is testing

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Who this might be right for
Chronic Myelogenous LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals 326
Testing effectiveness (Phase 2)Study completedNCT01445080
What this trial is testing

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Who this might be right for
Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07493408
What this trial is testing

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Who this might be right for
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Blastic Transformation of Chronic Myeloid LeukemiaPhiladelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)+1 more
The University of Hong Kong
Testing effectiveness (Phase 2)WithdrawnNCT00446173
What this trial is testing

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00827138
What this trial is testing

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

Who this might be right for
Chronic Myeloid Leukemia
Deciphera Pharmaceuticals, LLC 57
Early research (Phase 1)Ended earlyNCT01066468
What this trial is testing

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Who this might be right for
Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
Novartis Pharmaceuticals 3
Early research (Phase 1)WithdrawnNCT03414450
What this trial is testing

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Who this might be right for
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)+1 more
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Large-scale testing (Phase 3)Study completedNCT00265837
What this trial is testing

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+3 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 72
Post-approval studies (Phase 4)Ended earlyNCT02228382
What this trial is testing

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Who this might be right for
Previously Treated PH + CML
Pfizer 163
Large-scale testing (Phase 3)UnknownNCT00327262
What this trial is testing

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Who this might be right for
Chronic Myeloid Leukemia
Central European Leukemia Study Group 240
Large-scale testing (Phase 3)Study completedNCT01657604
What this trial is testing

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study

Who this might be right for
Chronic Myeloid Leukemia
University of Jena 717
Load More Results
45